BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-35@catalystbrief.girapphe.com
DTSTAMP:20261117T061548Z
LAST-MODIFIED:20261117T061548Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: TransThera Sciences (Nanjing)\, Inc. — Tinengotinib 8 mg
  [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Study of Tinengotinib VS. Physician
 's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma.
 \nSource: https://clinicaltrials.gov/study/NCT05948475\nhttps://catalystbr
 ief.girapphe.com/e/35?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/35?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
